SRR8942953
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.300
- MYC_TARGETS_V2+0.290
- MYOGENESIS+0.280
- P53_PATHWAY+0.250
- TNFA_SIGNALING_VIA_NFKB+0.190
- KRAS_SIGNALING_DN+0.180
- APICAL_JUNCTION+0.120
- IL6_JAK_STAT3_SIGNALING+0.120
- NOTCH_SIGNALING+0.080
- APOPTOSIS+0.070
Top 10 suppressed
- PROTEIN_SECRETION-0.610
- MYC_TARGETS_V1-0.370
- MTORC1_SIGNALING-0.360
- ANDROGEN_RESPONSE-0.350
- INTERFERON_ALPHA_RESPONSE-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
- FATTY_ACID_METABOLISM-0.270
- UV_RESPONSE_DN-0.260
- E2F_TARGETS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 52404_S128 | — | cohortA1 | 0.859 |
| 2 | GSM6454742 | — | D | 0.827 |
| 3 | TCGA-A2-A0CK-01A-11R-A22K-07 | — | A | 0.813 |
| 4 | GSM6454728 | — | D | 0.809 |
| 5 | SRR4195667 | — | — | 0.802 |
| 6 | MNG1087 | — | — | 0.794 |
| 7 | SRR8613760 | — | E | 0.787 |
| 8 | R109 | — | — | 0.786 |
| 9 | R76 | — | — | 0.783 |
| 10 | BS_PN2CE34A | low-grade glioma | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.060 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HYPOXIA | 0.060 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |